Etanercept biosimilar (Daewoong)

依那西普生物类似药（大熊制药）

Report date: 2025/07/31 13:30:10

Base Information

Drug NameEtanercept biosimilar (Daewoong)

Drug Alias Name依那西普生物仿制药（大熊制药）DWP-422

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar

Mechanisms of ActionTumor necrosis factor α inhibitorsTumor necrosis factor β inhibitors

TargetsTumor necrosis factor αTumor necrosis factor β

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsArthritis, Rheumatoid

ATC CodeL04AB01